Perspectives on Drug Repurposing

Schcolnik‐Cabrera, Alejandro; Juárez-López, Daniel; Dueñas‐González, Alfonso

doi:10.2174/0929867327666200831141337

Cited by 27 publications

(10 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The European Union [33] asserts that providing the right treatment to the right patient, at the right dose, at the right time, is paramount to uphold the healthcare system of any country. More so, identifying the patient population who will benefit from these expensive drugs will be crucial for patient care, as well as for the economic sustainability of a healthcare system [34,35]. Also, insufficient awareness of the centrality of Pathology and Laboratory Medicine (PALM) to a functioning healthcare system at policy and governmental level, with the resultant inadequate investment, has meant that efforts to enhance PALM in low-income and middle-income countries have been local, fragmented, and mostly unsustainable.…”

Section: Problem Statementmentioning

confidence: 99%

Assessing the effect of the lack of pharmaceutical manufacturing on healthcare provision in Botswana

Kgosietsile

Enwereji

Jordaan

2022

IJIMES

View full text Add to dashboard Cite

The lack of pharmaceutical products in Botswana has been a serious concern as citizens experience adverse health outcomes due to poor access to effective treatments. This study investigated the effect of the lack of pharmaceutical manufacturing on healthcare provision in Botswana. Systems Theory underpinned this study. This theory specifies the importance of component parts to work in unison to achieve a specific objective. An interpretivist research paradigm was adopted, which enhanced gaining knowledge on the fundamental reasons for the dearth of drugs/medicine in the Botswana healthcare system. Methodology: A qualitative research approach and an exploratory research design were selected for this study. These two methods enhanced the interviewing thirty-four participants such as doctors, nurses, pharmacists, inventory employees, and the public on the reasons for the shortage of drugs and how this affects citizens. Data were collected using open-ended interviews and responses were gathered from participants from a historical point of view. After the collection of data, an analysis was conducted using Atlas-ti Software (version 8.2). Themes and categories were generated and were discussed by corroborating them with the literature review findings. Findings: Findings from the study indicate that the reasons for medical stockout include poor planning by medical authorities, the emergence of new diseases, the lack of public private partnerships, logistic issues such as organizational red tape during tender decisions, ordering less than national demand by medical procurement officials, delays in import permits, delays by suppliers, and transportation challenges. The effects of medicine stockout include the healthcare system's inability to cure diseases, an increase of deaths, failure to control disease, continued stockouts, worsening of sicknesses, noncompliance of patients, failure to meet treatment outcomes, and an increased cost of medicines. The study recommends among others, that the government should support local pharmaceutical manufacturing, allow private companies to participate, and discourage sole distributorship. Originality/Value: This research Assessing the effect of the lack of pharmaceutical manufacturing on healthcare provision in Botswana

show abstract

Section: Problem Statementmentioning

confidence: 99%

Assessing the effect of the lack of pharmaceutical manufacturing on healthcare provision in Botswana

Kgosietsile

Enwereji

Jordaan

2022

IJIMES

View full text Add to dashboard Cite

show abstract

“…In recent years, the concept of drug repurposing (also known as “drug repositioning”, “reprofiling”, or “retasking”) is gaining increasing attention as a strategy for identifying new therapeutic applications of existing drugs or those under investigation outside the scope of the original medical indication [ 8 , 9 , 10 , 11 ]. Many researchers have demonstrated that non-traditional antitumor drugs have distinct anticancer actions and represent a safe and promising treatment option.…”

Section: Introductionmentioning

confidence: 99%

Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers

Meco

Attinà

Navarra

et al. 2023

IJMS

View full text Add to dashboard Cite

Repurposing approved non-antitumor drugs is a promising and affordable strategy in drug discovery to identify new therapeutic uses different from the original medical indication that may help increase the number of possible, effective anticancer drugs. The use of drugs in ways other than their original FDA-approved indications could offer novel avenues such as bypassing the chemoresistance and recurrence seen with conventional therapy and treatment; moreover, it can offer a safe and economic strategy for combination therapy. Recent works have demonstrated the anticancer properties of the FDA-approved drug Mebendazole. This synthetic benzimidazole proved effective against a broad spectrum of intestinal Helminthiasis. Mebendazole can penetrate the blood–brain barrier and has been shown to inhibit the malignant progression of glioma by targeting signaling pathways related to cell proliferation, apoptosis, or invasion/migration, or by increasing the sensitivity of glioma cells to conventional chemotherapy or radiotherapy. Moreover, several preclinical models and ongoing clinical trials explore the efficacy of Mebendazole in multiple cancers, including acute myeloid leukemia, brain cancer, oropharyngeal squamous cell carcinoma, breast cancer, gastrointestinal cancer, lung carcinoma, adrenocortical carcinoma, prostate cancer, and head and neck cancer. The present review summarizes central literature regarding the anticancer effects of MBZ in cancer cell lines, animal tumor models, and clinical trials to suggest possible strategies for safe and economical combinations of anticancer therapies in brain cancer. Mebendazole might be an excellent candidate for the treatment of brain tumors because of its efficacy both when used as monotherapy and in combination as an enhancement to standard chemotherapeutics and radiotherapy, due to its effectiveness on tumor angiogenesis inhibition, cell cycle arrest, apoptosis induction, and targeting of critical pathways involved in cancer such as Hedgehog signaling. Therefore, attention to MBZ repurposing has recently increased because of its potential therapeutic versatility and significant clinical implications, such as reducing medical care costs and optimizing existing therapies. Using new treatments is essential, particularly when current therapeutics for patients with brain cancer fail.

show abstract

“…Approximately 90% of experimental candidates fail to pass the clinical trials ( Mullard, 2022 ; Sun et al, 2022 ), owing to the unpredictable adverse reactions from new molecular structures. Drug repositioning (commonly known as “reuse of old drugs”) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indications ( Pushpakom et al, 2019 ; Schcolnik-Cabrera and Juárez-López, 2021 ). It can facilitate the drug development process, shorten the required time to 6.5 years and reduce the cost to 300 million dollars ( Nosengo, 2016 ; Breckenridge and Jacob, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Drug–disease association prediction with literature based multi-feature fusion

Kang

Hou

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Exploring the potential efficacy of a drug is a valid approach for drug development with shorter development times and lower costs. Recently, several computational drug repositioning methods have been introduced to learn multi-features for potential association prediction. However, fully leveraging the vast amount of information in the scientific literature to enhance drug-disease association prediction is a great challenge.Methods: We constructed a drug-disease association prediction method called Literature Based Multi-Feature Fusion (LBMFF), which effectively integrated known drugs, diseases, side effects and target associations from public databases as well as literature semantic features. Specifically, a pre-training and fine-tuning BERT model was introduced to extract literature semantic information for similarity assessment. Then, we revealed drug and disease embeddings from the constructed fusion similarity matrix by a graph convolutional network with an attention mechanism.Results: LBMFF achieved superior performance in drug-disease association prediction with an AUC value of 0.8818 and an AUPR value of 0.5916.Discussion: LBMFF achieved relative improvements of 31.67% and 16.09%, respectively, over the second-best results, compared to single feature methods and seven existing state-of-the-art prediction methods on the same test datasets. Meanwhile, case studies have verified that LBMFF can discover new associations to accelerate drug development. The proposed benchmark dataset and source code are available at: https://github.com/kang-hongyu/LBMFF.

show abstract

Perspectives on Drug Repurposing

Cited by 27 publications

References 99 publications

Assessing the effect of the lack of pharmaceutical manufacturing on healthcare provision in Botswana

Assessing the effect of the lack of pharmaceutical manufacturing on healthcare provision in Botswana

Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers

Drug–disease association prediction with literature based multi-feature fusion

Contact Info

Product

Resources

About